126 related articles for article (PubMed ID: 18372914)
1. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.
Tseng RC; Lin RK; Wen CK; Tseng C; Hsu HS; Hsu WH; Wang YC
Oncogene; 2008 Jul; 27(32):4488-96. PubMed ID: 18372914
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
3. RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of beta-catenin by interacting with betaTrCP.
Estrabaud E; Lassot I; Blot G; Le Rouzic E; Tanchou V; Quemeneur E; Daviet L; Margottin-Goguet F; Benarous R
Cancer Res; 2007 Feb; 67(3):1054-61. PubMed ID: 17283138
[TBL] [Abstract][Full Text] [Related]
4. SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis.
Tseng RC; Lee SH; Hsu HS; Chen BH; Tsai WC; Tzao C; Wang YC
Cancer Res; 2010 Jan; 70(2):543-51. PubMed ID: 20068157
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
8. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
Shao G; Berenguer J; Borczuk AC; Powell CA; Hei TK; Zhao Y
Cancer Res; 2006 May; 66(9):4566-73. PubMed ID: 16651406
[TBL] [Abstract][Full Text] [Related]
10. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
[TBL] [Abstract][Full Text] [Related]
11. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.
Koch A; Hrychyk A; Hartmann W; Waha A; Mikeska T; Waha A; Schüller U; Sörensen N; Berthold F; Goodyer CG; Wiestler OD; Birchmeier W; Behrens J; Pietsch T
Int J Cancer; 2007 Jul; 121(2):284-91. PubMed ID: 17373666
[TBL] [Abstract][Full Text] [Related]
13. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
14. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Albring KF; Huber O; Petersen I
Carcinogenesis; 2012 Oct; 33(10):1863-70. PubMed ID: 22791817
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
Moreno-Bueno G; Hardisson D; Sánchez C; Sarrió D; Cassia R; García-Rostán G; Prat J; Guo M; Herman JG; Matías-Guiu X; Esteller M; Palacios J
Oncogene; 2002 Nov; 21(52):7981-90. PubMed ID: 12439748
[TBL] [Abstract][Full Text] [Related]
16. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
17. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation.
Chen Y; Cui T; Knösel T; Yang L; Zöller K; Petersen I
Lung Cancer; 2011 Jul; 73(1):38-44. PubMed ID: 21095038
[TBL] [Abstract][Full Text] [Related]
18. P53 mutation as a source of aberrant beta-catenin accumulation in cancer cells.
Cagatay T; Ozturk M
Oncogene; 2002 Nov; 21(52):7971-80. PubMed ID: 12439747
[TBL] [Abstract][Full Text] [Related]
19. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
